Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS – Research Report) and Novo ...
Bitcoin breaks below $90,000 as crypto selloff deepens. Apple, Indonesia reportedly agree on terms to end iPhone 16 ban. Drug ...
Some health experts have call for further investigation, as figures show 82 deaths with suspected links to slimming drugs ...
Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Zoom Communications reported solid fourth-quarter earnings but a weaker-than-expected outlook. Broad markets are steady while defense stocks rally after no feared scenarios, including far-right ...
Novo Nordisk shares jumped 5.02% during early deals. On Monday, American telehealth firm Hims & Hers said in its earnings ...
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
Drug compounders have filed a lawsuit against the FDA for removing Novo Nordisk's Wegovy and Ozempic from its shortage list. This decision restricts compounders from selling cheaper versions, despite ...
Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results